Global Aptamers Market Scenario Highlighting Major Drivers & Trends, 2017-2022

Posted by Arslan on February 22nd, 2019

Aptamers can be generated quickly as compared to antibodies which is a plus point and hence they are used widely in treating diseases. The global aptamers market is expected to witness a probable increase in demand and hence growth which is influenced by factors associated with the aptamer product. The increase in the research and development activities along with increase in the investments in the biotechnological and pharmaceutical companies has driven the use of aptamers and hence the global aptamer market. Other advantages such as technological advancements followed by patent expiration of SELEX (Systematic Evolution of Ligands by Exponential enrichment technology), is likely to boost the growth of the aptamers market on a global scale. The development in aptamers technology has brought more effective, efficient and cost-reduced process for binding larger molecules as compared to antibodies. This is another aspect contributing to the growth of the global aptamers market. Also, the increasing use of aptamers in disease treatment and drug discovery have a significant impact ensuring its growth in a positive direction.

Aptamers are peptide molecules or oligonucleotides which bind to a target lipid, nucleic acid molecules or proteins. They are rapidly generated and applied in the specific detection, inhibition and characterization of proteins. They are used as detecting reagents, can be used as functional proteomic levels with antibodies, can be used as small molecules as well as pharmaceutical leads. They also can be engineered to attain higher affinity to a large number of target groups. Aptamers can be generated much faster than antibodies and hence can be used to cure diseases much faster than antibodies.

According to Fact.MR’s research report on the global aptamers market, the market is anticipated to show a robust growth rate and poised to register a CAGR of 25.5% during the forecasted period of 2017-2022.

Peptide Segment Shows High Tides

The peptide segment by product type has high potential as it grows at a super exponential rate and is anticipated to reflect a CAGR of 30.1% during the period of forecast of 2017 to 2022 and a high gain in the BPS by the end of 2022. The DNA segment shows high market share by value as of 2017, thereby establishing dominance over other segments. However, the current rate of peptide segment can take it up a notch to actually match the market share of DNA segment. The XNA and RNA segments have more or less similar growth rates during the forecast period. DNA, RNA and XNA, however, bound to experience loss in the BPS by the end of 2022.

Tug of War Between Diagnostics and Research and Developments

The diagnostics segment as well as research and developments segment by application have a tough fight from the growth standpoint. The research and developments segment, however, is anticipated to reflect a good growth rate which is a shade better than the diagnostics segment. North America region is bound to be more lucrative a region for the growth of these segments. The diagnostics segment, however, has a higher market share and it dominates the market. The market share of diagnostics segment is a bit less than two times than that of the research and development segment. It is almost eight times more than the other segment. Moreover, the diagnostics segment is expected to gain a high BPS by the end of 2022. The research and developments segment is poised to grow at a robust CAGR of 26.5% during the forecast period of 2017 to 2022.

Browse More Information about this Report @ https://www.factmr.com/report/173/aptamers-market

North America Region Portrays Global Domination

The North America region is supposed to be highly lucrative region for the aptamers market and shows a high market attractiveness index. With respect to revenue in 2017, the North America region is expected to dominate the global market and this trend is poised to continue over the forecast period. The region is expected to grow at a high growth rate to reflect a CAGR of 26.3% during the period of forecast. North America region is the largest market for all types of segments of the aptamers market. Following North America, Europe region also shows good growth potential in the aptamers market. The main reason for North America to prosper in this market is the technological advancement and the level of development that has taken place. The research and development centers also receive high investment support which make the most of them.

Pharmaceutical Companies and CRO Segments to Register Equal growth; Academic and Research Centers to show high pace

The academic and research centers by end user type are growing at a very high rate and poised to show a CAGR of 26.4% during the period of forecast. The pharmaceutical companies and the contract research organization (CRO) segments are expected to grow alongside one another, and are expected to show similar growth rates throughout the period of forecast. The bio-pharmaceutical companies segment shows the highest market share by revenue in 2017, and thereby dominates the global market and also reflects to gain a comparatively high BPS by the end of 2022.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global aptamers market through 2022, which include AM Biotech, Aptagen, LLC, Aptamer Sciences, Inc., Aptamer Group, Aptus Biotech, Base Pair Biotechnologies, Inc., NeoVentures Biotechnology Inc., Somalogic, Inc., TriLink BioTechnologies, LLC and Vivonics Inc.